Recent Updates
- Revenue was
$150.7 million for the third quarter of 2026, representing a 1% increase over the corresponding period of 2025. - Began global commercial shipments of Atera, with extraordinary early demand translating into ambitious new research programs spanning discovery, translational and biopharma research.
- Introduced Sentira, a cloud analysis platform to help customers turn complex biological datasets into insights, powered by NVIDIA accelerated computing for spatial data processing and
Anthropic's Claude for agentic AI analysis of single cell data.
"The biggest highlight of the quarter was the start of commercial shipments of Atera. Enthusiasm for the platform has continued to build, and we are incredibly excited to be putting instruments in customers' hands. We were also encouraged with the results across our broader business, driven by continued strength in consumables," said Serge Saxonov, Co-founder and CEO of
Third Quarter 2026 Financial Results
Revenue was
Gross margin was 75% for the third quarter of 2026, as compared to 67% for the corresponding prior year period. The increase in gross margin was primarily due to lower inventory write-downs and changes in product mix.
Operating expenses were
Operating loss was
Net loss was
Cash and cash equivalents and marketable securities were
2026 Financial Guidance
Webcast and Conference Call Information
About
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "outlook," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding
Disclosure Information
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
| Condensed Consolidated Statements of Operations (Unaudited) (In thousands, except share and per share data)
| |||||||
| | Three Months Ended | | Nine Months Ended | ||||
| | 2026 | | 2025 | | 2026 | | 2025 |
| Products and services revenue | $ 150,210 | | $ 148,019 | | $ 449,200 | | $ 430,999 |
| License and royalty revenue | 457 | | 983 | | 3,346 | | 45,794 |
| Revenue (1) | 150,667 | | 149,002 | | 452,546 | | 476,793 |
| Cost of products and services revenue (2) | 37,740 | | 48,695 | | 120,944 | | 145,957 |
| Gross profit | 112,927 | | 100,307 | | 331,602 | | 330,836 |
| Operating expenses: | | | | | | | |
| Research and development (2) | 52,929 | | 57,194 | | 166,567 | | 182,663 |
| Selling, general and administrative (2) | 76,055 | | 75,355 | | 221,093 | | 239,517 |
| Gain on settlement | — | | — | | (3,400) | | (49,900) |
| Total operating expenses | 128,984 | | 132,549 | | 384,260 | | 372,280 |
| Loss from operations | (16,057) | | (32,242) | | (52,658) | | (41,444) |
| Other income (expense): | | | | | | | |
| Interest income | 5,018 | | 5,199 | | 14,829 | | 13,156 |
| Interest expense | — | | 3 | | — | | — |
| Other income (expense), net | (7,437) | | (1,165) | | (12,139) | | 3,574 |
| Total other income (expense) | (2,419) | | 4,037 | | 2,690 | | 16,730 |
| Loss before provision for income taxes | (18,476) | | (28,205) | | (49,968) | | (24,714) |
| Provision for (benefit from) income taxes | 949 | | (733) | | 858 | | 2,578 |
| Net loss | $ (19,425) | | $ (27,472) | | $ (50,826) | | $ (27,292) |
| | | | | | | | |
| Net loss per share, basic and diluted | $ (0.15) | | $ (0.22) | | $ (0.39) | | $ (0.22) |
| | | | | | | | |
| Weighted-average shares used to compute net loss per | 130,805,838 | | 125,502,291 | | 129,570,736 | | 123,965,205 |
| (1) | The following table represents total revenue by source for the periods indicated (in thousands). Spatial includes the Company's Visium, Xenium and Atera products: |
| | |
| | Three Months Ended | | Nine Months Ended | ||||
| | 2026 | | 2025 | | 2026 | | 2025 |
| Instruments | | | | | | | |
| Single Cell | $ 3,782 | | $ 4,927 | | $ 12,092 | | $ 16,567 |
| Spatial | 3,076 | | 7,072 | | 13,689 | | 24,744 |
| Total instruments revenue | 6,858 | | 11,999 | | 25,781 | | 41,311 |
| Consumables | | | | | | | |
| Single Cell | 93,139 | | 92,519 | | 270,484 | | 262,416 |
| Spatial | 41,188 | | 35,373 | | 124,396 | | 103,017 |
| Total consumables revenue | 134,327 | | 127,892 | | 394,880 | | 365,433 |
| Services | 9,025 | | 8,128 | | 28,539 | | 24,255 |
| Products and services revenue | 150,210 | | 148,019 | | 449,200 | | 430,999 |
| License and royalty revenue | 457 | | 983 | | 3,346 | | 45,794 |
| Total revenue | $ 150,667 | | $ 149,002 | | $ 452,546 | | $ 476,793 |
| (1) | The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands): |
| | |
| | Three Months Ended | | Nine Months Ended | ||||
| | 2026 | | 2025 | | 2026 | | 2025 |
| | | | | | | | |
| | $ 82,093 | | $ 77,246 | | $ 240,895 | | $ 267,555 |
| | 3,849 | | 2,625 | | 10,172 | | 9,044 |
| Total | 85,942 | | 79,871 | | 251,067 | | 276,599 |
| | 38,753 | | 41,624 | | 115,577 | | 108,253 |
| | | | | | | | |
| | 15,216 | | 15,189 | | 46,021 | | 55,242 |
| | 10,756 | | 12,318 | | 39,881 | | 36,699 |
| Total | 25,972 | | 27,507 | | 85,902 | | 91,941 |
| Total revenue | $ 150,667 | | $ 149,002 | | $ 452,546 | | $ 476,793 |
|
* Includes license and royalty revenue. | |||||||
| (2) Includes stock-based compensation expense as follows: |
| |
| | Three Months Ended | | Nine Months Ended | ||||
| (in thousands) | 2026 | | 2025 | | 2026 | | 2025 |
| Cost of revenue | $ 2,157 | | $ 2,011 | | $ 5,911 | | $ 6,481 |
| Research and development | 8,940 | | 11,318 | | 30,168 | | 38,037 |
| Selling, general and administrative | 11,999 | | 11,935 | | 35,275 | | 39,067 |
| Total stock-based compensation expense | $ 23,096 | | $ 25,264 | | $ 71,354 | | $ 83,585 |
| Condensed Consolidated Balance Sheets (Unaudited) (In thousands)
| |||
| |
| |
|
| Assets | | | |
| Current assets: | | | |
| Cash and cash equivalents | $ 526,187 | | $ 473,966 |
| Marketable securities | 49,493 | | 49,443 |
| Accounts receivable, net | 55,701 | | 47,013 |
| Other receivables | 3,055 | | 35,480 |
| Inventory | 64,629 | | 56,341 |
| Prepaid expenses and other current assets | 19,566 | | 22,208 |
| Total current assets | 718,631 | | 684,451 |
| Property and equipment, net | 210,239 | | 226,711 |
| Operating lease right-of-use assets | 54,759 | | 60,450 |
| | 6,918 | | 4,511 |
| Intangible assets, net | 58,663 | | 62,329 |
| Other noncurrent assets | 13,919 | | 2,913 |
| Total assets | $ 1,063,129 | | $ 1,041,365 |
| Liabilities and stockholders' equity | | | |
| Current liabilities: | | | |
| Accounts payable | $ 21,594 | | $ 12,733 |
| Accrued compensation and related benefits | 39,657 | | 42,500 |
| Accrued expenses and other current liabilities | 32,181 | | 39,971 |
| Deferred revenue | 22,956 | | 23,902 |
| Operating lease liabilities | 11,946 | | 10,985 |
| Contingent consideration, current | 12,036 | | 23,363 |
| Total current liabilities | 140,370 | | 153,454 |
| Contingent consideration, noncurrent | 5,842 | | 1,237 |
| Operating lease liabilities, noncurrent | 63,846 | | 73,376 |
| Deferred revenue, noncurrent | 8,530 | | 10,501 |
| Other noncurrent liabilities | 6,505 | | 6,471 |
| Total liabilities | 225,093 | | 245,039 |
| Stockholders' equity: | | | |
| Preferred stock | — | | — |
| Common stock | 2 | | 2 |
| Additional paid-in capital | 2,399,254 | | 2,306,690 |
| Accumulated deficit | (1,561,417) | | (1,510,591) |
| Accumulated other comprehensive income | 197 | | 225 |
| Total stockholders' equity | 838,036 | | 796,326 |
| Total liabilities and stockholders' equity | $ 1,063,129 | | $ 1,041,365 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-reports-third-quarter-2026-financial-results-302931240.html
SOURCE